194 related articles for article (PubMed ID: 22762031)
21. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
23. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
[TBL] [Abstract][Full Text] [Related]
24. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
25. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
Liisborg C
Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
[TBL] [Abstract][Full Text] [Related]
26. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.
Zhang X; Hu T; Wu Z; Kang Z; Liu W; Guan M
Int J Hematol; 2012 Nov; 96(5):611-6. PubMed ID: 23054641
[TBL] [Abstract][Full Text] [Related]
27. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].
Kim JT; Cho YG; Choi SI; Lee YJ; Kim HR; Jang SJ; Moon DS; Park YJ; Park G
Korean J Lab Med; 2010 Dec; 30(6):567-74. PubMed ID: 21157140
[TBL] [Abstract][Full Text] [Related]
28. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
Singdong R; Siriboonpiputtana T; Chareonsirisuthigul T; Kongruang A; Limsuwanachot N; Sirirat T; Chuncharunee S; Rerkamnuaychoke B
Asian Pac J Cancer Prev; 2016 Oct; 17(10):4647-4653. PubMed ID: 27892678
[TBL] [Abstract][Full Text] [Related]
29. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.
Bang SM; Lee JS; Ahn JY; Lee JH; Hyun MS; Kim BS; Park MR; Chi HS; Kim HY; Kim HJ; Lee MH; Kim H; Won JH; Yoon HJ; Oh DY; Nam EM; Bae SH; Kim BK;
Thromb Haemost; 2009 Mar; 101(3):547-51. PubMed ID: 19277418
[TBL] [Abstract][Full Text] [Related]
30. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
31. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms].
Yan J; Ding YW; Wang PY; Wu YP; Zhang HC; Liu LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1540-1547. PubMed ID: 34627437
[TBL] [Abstract][Full Text] [Related]
33. [Expression level of Wilms' tumor 1 gene and its correlation with clinical features in patients with myeloproliferative neoplasms].
Liu C; Wu SY; Zhang AB; Luo P; Zhou Y; Liu Y; Zuo XL
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3658-3664. PubMed ID: 38018065
[No Abstract] [Full Text] [Related]
34. [Correlative study between JAK2 mutation and thrombosis in patients with myeloproliferative neoplasm].
Xia L; Ding KY; Cai XY; Zhu WB; Liu X; Yang HZ; Wan X; Wu LL; Zeng QS; Wu JS
Zhonghua Xue Ye Xue Za Zhi; 2010 Sep; 31(9):590-3. PubMed ID: 21122317
[TBL] [Abstract][Full Text] [Related]
35. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
Haybar H; Khodadi E; Shahjahani M; Saki N
Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
[TBL] [Abstract][Full Text] [Related]
37. Comparative study of different methodologies to detect the
Didone A; Nardinelli L; Marchiani M; Ruiz ARL; de Lima Costa AL; Lima IS; Santos NM; Sanabani SS; Bendit I
Pract Lab Med; 2016 Apr; 4():30-37. PubMed ID: 28856190
[TBL] [Abstract][Full Text] [Related]
38. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
39. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics of a patient with
Jiang YZ; Wei ZL; Wang NN; Huang C; Huang J; Yan JW; Wang R; Yu ZZ; Huang DP
Hematology; 2022 Dec; 27(1):1290-1293. PubMed ID: 36476114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
